Direct delivery into circulation allows the peptide to reach target tissues without the absorption loss associated with oral forms
Most peptides don't require this
Compounded preparations are dispensed by a licensed 503A pharmacy pursuant to a prescription based on documented clinical need
AOD-9604 Peptide Regulatory Status in Canada Health Canada Regulatory Status - Unapproved Investigational Compound AOD-9604 has never been authorized by Health Canada or any other major health authority worldwide for any human or veterinary indication
Published Phase 2 clinical trial data used doses of 1mg, 4mg, 8mg, and 12mg administered weekly via subcutaneous injection
For TB-500 / thymosin beta-4, the supportive rationale is the well-documented role of thymosin beta-4 in actin regulation, cell migration and wound healing again, largely from cell and animal models rather than human recovery trials